Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Hepatol. Jul 28, 2017; 9(21): 930-944
Published online Jul 28, 2017. doi: 10.4254/wjh.v9.i21.930
Table 5 Outcome of patients
Total numberSFSS n (%) 20 (100)-No SFSS n (%) 154 (100)-P value
Overall mortality15 (75)Grade62 (40.3)Grade0.003
Cause of mortality and their Dindo-Clavien score
Sepsis from causes other than SFSS0-19 (30.6)V0
SFSS (sepsis, graft failure, DIC, renal failure, ARDS, MOF)13 (86.7)V0-
MOF from causes other than SFSS0-11 (17.7)V
Post-operative bleeding2 (13.3)V10 (16.1)V
Intra-operative bleeding0-8 (12.9)V
PVT0-4 (6.4)V
Renal impairment from causes other than SFSS0-2 (3.2)V
Metastatic cholangiocarcinoma0-2 (3.2)V
Early graft dysfunction from causes other than SFSS0-2 (3.2)V
HCC recurrence0-2 (3.2)V
Ischemic reperfusion injury0-1 (1.6)V
HAT0-1 (1.6)V
6-mo survival6 (30)-108 (70.1)-0.000
1-yr survival6 (30)-101 (65.6)-0.002
3-yr survival5 (25)-95 (61.7)-0.002
5-yr survival5 (25)-94 (61)-0.002
7-yr survival5 (25)-92 (59.7)-0.003
10-yr survival5 (25)-92 (59.7)-0.003
Survival per months (mean ± SD)16.3 ± 28.9-39.9 ± 34.3-0.002
Graft survival4 (20)89 (57.8)0.001
Graft survival per months (mean ± SD)16.2 ± 28.939.7 ± 34.30.003